Capillary Biomedical, Inc. (CapBio), headquartered in Irvine, California, is developing a novel 7-day infusion set for use with insulin pumps for the intensive management of diabetes. The company has assembled a veteran team of diabetes technology entrepreneurs, conducted extensive preclinical research, developed a minimal viable product, and filed multiple patent applications. In 2018, the company completed a series seed preferred equity financing syndicated among leading angel group that was subsequently expanded to include the JDRF T1D. The company is presently conducting clinical feasibility trials of its SteadiFlow™ cannula technology and is conducting bench testing in support of regulatory approval to conduct pivotal study of its 7-day SteadiSet™ infusion set.